Evaluation of off-label rapamycin use to promote healthspan in 333 adults, 2023, Kaeberlein et al

Evaluation of off-label rapamycin use to promote healthspan in 333 adults

Tammi L Kaeberlein, Alan S Green, George Haddad, Johnny Hudson, Anar Isman, Andy Nyquist, Bradley S Rosen, Yousin Suh, Sajad Zalzala, Xingyu Zhang, Mikhail V Blagosklonny, Jonathan Y An, Matt Kaeberlein

Abstract
Rapamycin (sirolimus) is an FDA-approved drug with immune-modulating and growth-inhibitory properties. Preclinical studies have shown that rapamycin extends lifespan and healthspan metrics in yeast, invertebrates, and rodents. Several physicians are now prescribing rapamycin off-label as a preventative therapy to maintain healthspan. Thus far, however, there is limited data available on side effects or efficacy associated with use of rapamycin in this context. To begin to address this gap in knowledge, we collected data from 333 adults with a history of off-label use of rapamycin by survey. Similar data were also collected from 172 adults who had never used rapamycin. Here, we describe the general characteristics of a patient cohort using off-label rapamycin and present initial evidence that rapamycin can be used safely in adults of normal health status.

Link | PDF (GeroScience) [Open Access]

 

Interestingly, only one condition was significantly more common in off-label rapamycin users than non-users: canker sores.

It says things like depression and anxiety were less common, but I don't think any causality can be inferred.

 

Here it says Rapamycin can cause insulin resistance,I already suspect I have that
Once again on rapamycin-induced insulin resistance and longevity: despite of or owing to
https://pmc.ncbi.nlm.nih.gov/articles/PMC3384435/